Helsinn Group, MEI Pharma enter deal for Pracinostat development
Tuesday, August 09, 2016
Helsinn Group and Mei Pharma enter strategic agreement for the development and commercialization of pracinostat for the treatment of acute myeloid leukemia and other hematologic diseases.
To receive $20 million in near-term cash payments, plus up to $444 million in potential milestone payments as well as royalties on future sales.
Helsinn, co to collaborate to explore optimal dosing regimen of pracinostat in combination with azacitidine for treatment of high-risk mds.
Agreement enables Helsinn to expand into oncology therapeutics with new phase iii-ready asset.
Source : reuters.com
